Creative Biolabs is a forward-looking antibody service provider. With years of experience in discovering and developing next-generation antibody therapies in the aim of solving unmet health problems worldwide, we currently provide a most comprehensive portfolio of antibody function assays to in-depth validate your antibody lead in an early stage. Especially, we offer different neutralization assays to evaluate the potency of your antibody candidates to neutralize or block inflammatory cytokines.
Proinflammatory cytokines are potent mediators of numerous biological processes and are tightly regulated in the body. Persistent and excessive production of inflammatory cytokines can initiate and derive many pathologies, including incidences of autoimmunity and cancer. Therefore, therapies that regulate the activity of inflammatory cytokines, e.g., by neutralizing them by using blocking antibodies, have been extensively investigated over the past decades. A variety of cytokines have been reported to play an important role in the disease pathogenesis, including tumor necrosis factor α (TNFα), interleukin-6 (IL-6), IL-23, IL-17, etc. For instance, Infliximab (chimeric TNFα-specific antibody) has proven to be effective in treating inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Siltuximab (chimeric IL-6-specific mAb) has been approved for multi-center trials of Castleman’s disease treatment. In short, targeting inflammatory cytokines with antibodies has demonstrated preferable clinical outcomes in patients with different diseases.
Fig.1 Biological drugs strategies for targeting inflammatory cytokines. (Rider, 2016)
Creative Biolabs widely provides cost-effective cytokine neutralization assay services for global customers to support your drug discovery and screening. In the neutralization assays, we offer two main service models including the primary cell system and reporter gene cell line system. The final detection endpoint of these two models will be different, and the scenarios used will also have different focuses. We can customize the service according to the specific project needs of customers, you can refer to the following table for specific information. At the same time, we are confident in offering these target-related cytokine neutralization assays: IL-6, TNF; VEGF; IL-12, IL-23, ......
Assay Approaches List
Representative Data
| Approaches | Final Detection Endpoint | Application Scenarios | Advantages |
| Primary Cell System | Biological response detection: such as cytokine release, and proliferation test. | Final leads screening and characterization. | More closer to the real situation. |
| Reporter Gene Cell Line System | Measurement of Reporter gene activity. | Function screening was used in the early stage of research. | More convenient and economical. |
Representative data: In this study, researchers developed and validated a novel anti-IL12p40 antibody. In the cytokine neutralization assay, the antibody effectively suppressed the production of IFNγ induced by IL-12 and the production of IL-17 induced by IL-23 in vitro, respectively.
Fig.2 The h6F6 novel antibody exhibited significant inhibition of IL-12-induced IFNγ production and IL-23-induced IL-17 production.2
With the help of our professional scientists, Creative Biolabs is committed to guiding global customers to a series of therapeutic antibody functional analysis solutions. We have established a number of assays aiming to offer streamlined functional characterization services from product efficacy assessment to mechanism of action investigations. If you are interested in our services, please feel free to contact us or send us an inquiry.
References
For Research Use Only.
